(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
ViiV to trial twice-yearly HIV antibody dosing following Phase IIb success
ViiV Healthcare is exploring a twice-yearly dosing regimen for its experimental HIV therapy, N6LS, following promising results from its Phase IIb Embrace trial.
The study found that 96% of patients receiving intravenous (IV) N6LS every four months, combined with monthly cabotegravir injections, maintained undetectable viral loads. Similarly, 88% of patients receiving a subcutaneous version of N6LS also achieved viral suppression.
Encouraged by these results, ViiV plans to test a six-month IV dosing schedule in combination with Cabenuva (cabotegravir and rilpivirine) in the next phase of the Embrace trial. While treatment-related adverse events (AEs) were reported, no serious safety concerns emerged.
N6LS is a broadly neutralizing antibody (bNAb) designed to block multiple HIV strains from entering healthy cells. If approved, it could generate an estimated $247 million in revenue by 2031.
Meanwhile, Gilead is preparing for a Phase III trial of its once-yearly lenacapavir PrEP, while reductions in USAID funding may impact global HIV research efforts.
23-03-2025